Literature DB >> 16461528

Optimisation strategies and justification: an example in uterine artery embolisation for fibroids.

S Vetter1, F W Schultz, E-P Strecker, J Zoetelief.   

Abstract

Radiation risk has to be justified and optimised. This study discusses the radiation risk of uterine artery embolisation (UAE) for the treatment of fibroids. A total of 70 consecutive UAE dosimetry parameters were assessed. Using Monte Carlo simulation, organ and effective doses and dose conversion coefficients (DCCs) (mSv Gy cm(-2)) were calculated. During UAE optimisation, avoidance of oblique views and use of last-image-hold (LIH) documentation instead of digital subtraction angiography (DSA) were investigated. Mean dose-area product (DAP) was 37.1 Gy cm2 (median 23.7 Gy cm2) and mean fluoroscopy time was 18.4 min (median 16.6 min). Dose values decreased as the study progressed: mean DAP for patients 1-21, 68.5 Gy cm2; patients 22-43, 35.7 Gy cm2; and patients 44-69, 13.0 Gy cm2. Average DCC for DSA image procedures was 0.572, yielding a mean effective dose of 29.6 mSv (median 17.1 mSv). For LIH-only procedures, an average DCC of 0.813 was estimated [using mean effective dose: 10.6 mSv (median 8.1 mSv)].

Entities:  

Mesh:

Year:  2006        PMID: 16461528     DOI: 10.1093/rpd/nci717

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  2 in total

1.  Uterine artery embolization immediately preceding laparoscopic myomectomy.

Authors:  Kara N Goldman; Jennifer E Hirshfeld-Cytron; Mary-Ellen Pavone; Andrew P Thomas; Robert L Vogelzang; Magdy P Milad
Journal:  Int J Gynaecol Obstet       Date:  2011-11-17       Impact factor: 3.561

2.  A Retrospective, Single-Center Study of Technical-Procedural Factors Affecting Radiation Dose During Prostatic Artery Embolization.

Authors:  Hippocrates Moschouris; Konstantinos Stamatiou; Nektarios Spanomanolis; Anastasios Vasilopoulos; Spiros Tzamarias; Katerina Malagari
Journal:  Cureus       Date:  2022-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.